Reading SYRE? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track SYRE free→Reading SYRE? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track SYRE free→
NASDAQHealth CareBiotechnologySnapshot 2026-06-15
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is neutral, and management's recent track record has been fairly steady. The company was unprofitable over the past year, so its earnings quality can't be assessed. Risk is elevated, and the sector backdrop is a headwind, with SYRE trading below typical compared to sector peers. Peer multiples imply a price about 194% below where it trades (it looks expensive on this basis); the read is rich, as it trades above peer multiples, and the longer horizon does not make that back through growth. If SYRE cuts guidance on the next call, that could be a meaningful negative. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 1 valuation methods, at three horizons. Current price $83.58. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
We can't anchor a clean multiple for SYRE right now, so treat our $23 fair value as low-confidence. Analysts: $49–$115. Not investment advice.
$49.00 – $115.00 (median $90.00) · 12 analysts · as of 2026-06-04
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The market is pricing in roughly 248% of near-term growth above a flat-multiple fair value; not enough history to forecast a comparison. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Flags: expensive valuation, a turbulent sector regime (Heating).
For similar setups historically (n=2,301): about 43% saw a 20%+ drawdown, and roughly 77% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 50% of the time over the next year (vs 57% for the rest of the cohort, n=3115).
Over the trailing year it converted 1.03x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, Fed net liquidity, long-term interest rates.
6 material management or governance events in the past 24 months, led by legal/regulatory items. Historically, Health Care names rated neutral grew net income 58% of the time over the next year (vs 50% for the rest of the cohort, n=842).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-0.70 → $-0.71 (-2.0% / 30d). 4 raised, 7 cut, 13 covering analysts.
0 upgrades, 0 downgrades / 30d, 1 maintained. 100% of analysts rate Buy.
2 PT revisions / 30d. Avg target 45.2% above current price.
0 positive, 0 negative / 30d.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$229.
How much price usually moves either way.
On a bad day, this stock has moved -$521.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $1,679.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
Composite insight fell by 12.0 points (from 2.1 to -9.9).
As of June 15, 2026, the composite insight fell. Risk remained elevated. The sector backdrop was noted as a headwind. Valuation was described as expensive, trading above peer multiples.
as of 2026-06-15
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Earnings results can show how healthy a company is. They also hint at future plans.
Confirms one read:Earnings report shows revenue growth or better margins than before.
Confirms the other:Earnings report shows ongoing losses or falling revenue.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for SYRE yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As discussed in
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Looks more expensive than peers.
Self-history needs ~20 months of data.
Trailing four: 2024-Q2, 2024-Q3, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Biotechnology.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
SYRE Spyre Therapeutics, Inc. | Below typical Show detailsSector percentile: 20 of 100 | expensive | elevated |
ABBV AbbVie | Above typical Show detailsSector percentile: 86 of 100 | fair | low |
AMGN Amgen | Above typical Show detailsSector percentile: 77 of 100 | full | moderate |
GILD Gilead Sciences | Above typical Show detailsSector percentile: 100 of 100 | fair | moderate |
VRTX Vertex Pharmaceuticals | Above typical Show detailsSector percentile: 80 of 100 | expensive | moderate |
Not investment advice. As of 2026-06-15.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-15.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue the development of SPY001 by advancing the Phase 2 SKYLINE trial for moderate-to-severely active UC.
Newly stated in 2026-Q1. The company announced positive initial 12-week induction topline data from Part A of the Phase 2 SKYLINE trial. This indicates progress in the development of SPY001 for moderate-to-severely active UC. However, financials show a net income loss of $69 million in 2026-Q1, suggesting limited financial progress despite clinical advancements.
“Positive initial 12-week induction topline data from Part A of the Phase 2 SKYLINE trial.”
Pioneer long-acting antibodies and combinations to redefine the standard of care for inflammatory bowel disease.
Newly stated in 2026-Q1. The company aims to pioneer long-acting antibodies for IBD, with six expected POC. Despite this strategic focus, financials reveal a net income loss of $69 million in 2026-Q1, indicating financial challenges alongside product development efforts.
“Highlighted its 2026 priorities including six expected POC for long-acting antibodies.”
Address ongoing financial losses and negative cash flow from operations.
Newly stated in 2026-Q1. The company faces significant financial challenges, reporting a net income loss of $69 million and cash from operations of -$57 million in 2026-Q1. This indicates ongoing financial strain, with limited progress in managing losses and cash flow.
“Reported a net income loss of $69 million and cash from operations of -$57 million.”
Why it matters: If healthcare sector growth picks up, it could benefit Spyre's performance.
Confirms:Healthcare sector revenue growth returns to above 10% year over year.
Disproves:Healthcare sector revenue growth is slowing down. It is now below 10% year over year.
Results of Operations and Financial Condition. On May 5, 2026, Spyre Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2026. A copy of the press release is furnished as Exhibit 99.1 to this report. The information in this Item 2.02, including Exhibit 99.1 to this report, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise…
Results of Operations and Financial Condition. On April 13, 2026, Spyre Therapeutics, Inc. (the “Company”) announced that while the Company has not finalized its full financial results for the quarter ended March 31, 2026, the Company expects to report that it had approximately $741 million of cash, cash equivalents and marketable securities as of March 31, 2026. This amount includes $30 million of legacy asset disposition proceeds collected during the quarter ended March 31, 2026, of which a…
Entry into a Material Definitive Agreement On April 14, 2026, Spyre Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, Goldman Sachs & Co. LLC, Evercore Group L.L.C. and Guggenheim Securities, LLC, as the representatives of the underwriters named therein (the “Underwriters”), relating to the offer and sale (the “Offering”) of 6,500,000 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”…
Other Events. On April 13, 2026, the Company announced positive initial 12-week induction topline data from Part A of the Phase 2 SKYLINE trial of SPY001 for the treatment of moderate-to-severely active UC. Additionally, the Company announced that recruitment for Part A of the SKYLINE Trial is now closed and enrollment is open for Part B, which includes three monotherapy cohorts (SPY001, SPY002, and SPY003) and three combination cohorts (SPY120, SPY130, and SPY230) into which participants may…